Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals, reports acquisition and disposal of company stock.

EVP Chief Patient & Ext Af Off Amit Sachdev reports acquisition of 6,211 shares of Vertex Pharmaceuticals common stock through a restricted stock unit award.

Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals, reports acquiring 19,015 shares of common stock.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reports the acquisition of 5,546 shares of common stock and the disposal of an unquantified amount on February 12, 2025.

Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals, reports acquiring 4,437 shares of common stock and now beneficially owns 20,767 shares.

EVP, Chief Technical Operations Officer of Vertex Pharmaceuticals, Edward Morrow Atkinson III, reports the acquisition of 6,211 shares of common stock on February 12, 2025, through a restricted stock unit award.

Stuart A. Arbuckle, EVP, COO of Vertex Pharmaceuticals, reports the acquisition of 7,903 restricted stock units.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the acquisition of 2,080 shares of common stock through a restricted stock unit award.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, acquired 5,324 shares of common stock through a restricted stock unit award.

Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, reported the disposal of 2,649 shares of common stock on February 10, 2025, to cover tax obligations.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Amit Sachdev, EVP Chief Patient & External Affairs Officer at Vertex Pharmaceuticals, reported the disposal of 2,056 shares of common stock to cover tax obligations.

Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals, reported disposing of 8,300 shares of common stock on February 10, 2025.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reports the disposal of 2,142 shares of common stock to cover tax obligations.

EVP and Chief Legal Officer of Vertex Pharmaceuticals, Jonathan Biller, reports the sale of company stock under a pre-arranged trading plan.

Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports a transaction involving common stock, including the disposition of shares to cover tax obligations.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of common stock on February 10th and 11th, 2025.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, disposed of 2,142 shares of common stock on February 10, 2025, to cover tax obligations.

Charles Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, reports the acquisition of performance shares related to performance stock unit awards.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, reports acquiring performance shares related to performance stock unit awards.

Amit Sachdev, EVP Chief Patient & External Affairs Officer at Vertex Pharmaceuticals, acquired shares of common stock following the certification of performance goal attainment related to performance stock unit awards.

Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals, acquired 15,414 shares of common stock on February 4, 2025, following the certification of performance goal attainment related to a performance stock unit award.

CEO Reshma Kewalramani reports acquisition of Vertex Pharmaceuticals common stock related to performance stock unit awards.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reports the acquisition of common stock related to performance stock unit awards.

Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals, reports the acquisition of 4,744 common stock shares and disposal of an unspecified amount on February 4, 2025, related to performance stock units.

EVP Edward Morrow Atkinson III of Vertex Pharmaceuticals reports acquisition of common stock following the certification of performance goal attainment related to performance stock unit awards.

Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports acquisition of shares related to performance stock unit awards.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the vesting of performance-based stock awards.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the acquisition of performance shares related to performance stock unit awards.